Biopharma and medtech half-year review 2021
Evaluate Vantage’s latest half-year report, free to download now, examines the emerging trends shaping the biopharma and medtech sectors. Winners and losers on the stock market are identified; developers that brought pandemic treatments or vaccines to market are reaping the benefits, while in medtech those making devices used in orthopaedics or cardiovascular procedures are surging back. The financing climate remained strong in the first half, with some record-setting numbers emerging. Biotech flotations raised $9bn, while private start-ups raised $15bn in venture cash, according to Evaluate Pharma, the data source for this report. In medtech mergers are happening at a healthy pace: deals worth $31.5bn were closed in the first six months of 2021, outstripping the total for all of 2020. A quiet six months for M&A in biopharma, though, suggests that high valuations are hindering deal-making. But biopharma remains a highly active in-licensor of innovation, and for the first time this report contains insights from BioSciDB, acquired by Evaluate Ltd earlier this year. For a deeper dive into these insights and more download the report for free: Biopharma and medtech half year review 2021.